Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCMNASDAQ:IBRXNYSE:OGNNASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCMHUTCHMED$15.19-0.7%$14.06$11.51▼$21.50$2.65B0.55100,359 shs21,584 shsIBRXImmunityBio$2.90-1.0%$2.59$1.83▼$7.63$2.56B0.147.33 million shs4.46 million shsOGNOrganon & Co.$9.18-3.7%$10.61$8.01▼$23.10$2.39B0.583.34 million shs1.95 million shsTSHATaysha Gene Therapies$2.80+0.4%$1.98$1.05▼$4.32$601.05M0.93.01 million shs1.36 million shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCMHUTCHMED+4.08%+15.65%+1.19%-4.49%-18.96%IBRXImmunityBio+8.12%+19.11%+39.52%-2.01%-52.36%OGNOrganon & Co.+1.11%+4.15%+9.34%-35.78%-54.29%TSHATaysha Gene Therapies+0.36%+14.34%+13.41%+65.09%-24.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCMHUTCHMED1.3104 of 5 stars2.02.00.00.02.10.01.9IBRXImmunityBio2.3221 of 5 stars3.61.00.00.03.01.70.6OGNOrganon & Co.4.9113 of 5 stars3.34.01.73.71.83.33.1TSHATaysha Gene Therapies3.898 of 5 stars4.51.00.00.03.83.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCMHUTCHMED 2.00Hold$19.0024.79% UpsideIBRXImmunityBio 3.20Buy$12.25310.39% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0094.68% UpsideTSHATaysha Gene Therapies 3.00Buy$7.57170.89% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, OGN, HCM, and IBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025IBRXImmunityBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/3/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.006/3/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $11.006/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $8.005/29/2025TSHATaysha Gene TherapiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/29/2025TSHATaysha Gene TherapiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$5.00 ➝ $6.005/29/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $9.005/28/2025IBRXImmunityBioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/20/2025IBRXImmunityBioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$4.25 ➝ $5.005/16/2025TSHATaysha Gene TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $9.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCMHUTCHMED$630.20M4.21$0.62 per share24.51$4.27 per share3.57IBRXImmunityBio$31.22M84.38N/AN/A($0.88) per share-3.39OGNOrganon & Co.$6.29B0.38$2.96 per share3.12($0.27) per share-34.24TSHATaysha Gene Therapies$7.22M83.05N/AN/A$0.40 per share6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCMHUTCHMED$100.78MN/A0.0010.43N/AN/AN/AN/A6/18/2025 (Estimated)IBRXImmunityBio-$583.20M-$0.58N/AN/AN/A-8,016.83%N/A-110.02%8/11/2025 (Estimated)OGNOrganon & Co.$864M$2.882.782.470.9013.49%431.62%8.03%8/5/2025 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.344.44N/AN/A-229.67%-106.36%-49.16%8/11/2025 (Estimated)Latest TSHA, OGN, HCM, and IBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025TSHATaysha Gene Therapies-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million5/12/2025Q1 2025IBRXImmunityBio-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCMHUTCHMEDN/AN/AN/AN/AN/AIBRXImmunityBioN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.87%+25.99%2.78%N/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ALatest TSHA, OGN, HCM, and IBRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCMHUTCHMED0.072.812.68IBRXImmunityBioN/A2.682.64OGNOrganon & Co.17.731.701.21TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCMHUTCHMED8.82%IBRXImmunityBio8.58%OGNOrganon & Co.77.43%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipHCMHUTCHMED3.60%IBRXImmunityBio76.79%OGNOrganon & Co.1.96%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIBRXImmunityBio590882.62 million115.67 millionOptionableOGNOrganon & Co.10,000259.96 million253.93 millionNot OptionableTSHATaysha Gene Therapies180214.66 million199.41 millionOptionableTSHA, OGN, HCM, and IBRX HeadlinesRecent News About These CompaniesTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00 at Canaccord Genuity GroupJune 5 at 1:19 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Major Shareholder Buys $2,062,500.00 in StockJune 5 at 12:01 AM | marketbeat.comTaysha Gene Therapies Releases TSHA-102 Clinical Program UpdatesJune 4 at 5:52 PM | insidermonkey.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Insider Buying ActivityJune 4 at 10:26 AM | marketbeat.comRetail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial DataJune 4 at 9:34 AM | msn.comPaul B. Manning Buys 750,000 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) StockJune 4 at 5:45 AM | insidertrades.comTaysha Gene Therapies Highlights TSHA-102 Program Advancements for Rett Syndrome at 2025 IRSF Scientific MeetingJune 3 at 5:41 PM | quiverquant.comTaysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical ProgramJune 3 at 5:17 PM | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Given "Buy" Rating at Needham & Company LLCJune 3 at 1:43 PM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $11.00June 3 at 8:11 AM | marketbeat.com6TSHA : Where Taysha Gene Therapies Stands With AnalystsJune 3 at 12:28 AM | benzinga.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Stake Lessened by Deutsche Bank AGJune 2 at 3:42 AM | marketbeat.comBank of America Corp DE Boosts Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)June 1, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, JMP Securities Analyst SaysMay 31, 2025 | americanbankingnews.comTaysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of ...May 30, 2025 | morningstar.comTaysha Gene Therapies (TSHA) Price Target Raised by JMP on Positive Rett Syndrome Trial DataMay 30, 2025 | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up on Analyst UpgradeMay 30, 2025 | marketbeat.comJMP Securities Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceMay 30, 2025 | marketbeat.comChardan Capital Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock PriceMay 30, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $9.00May 30, 2025 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up Following Analyst UpgradeMay 30, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookAnalysts Say Unilever Has the Leverage to Hit New HighsBy Thomas Hughes | May 15, 2025View Analysts Say Unilever Has the Leverage to Hit New HighsTSHA, OGN, HCM, and IBRX Company DescriptionsHUTCHMED NASDAQ:HCM$15.19 -0.11 (-0.72%) As of 12:46 PM EasternHUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.ImmunityBio NASDAQ:IBRX$2.90 -0.03 (-1.02%) As of 01:04 PM EasternImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.Organon & Co. NYSE:OGN$9.18 -0.35 (-3.67%) As of 12:59 PM EasternOrganon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.Taysha Gene Therapies NASDAQ:TSHA$2.80 +0.01 (+0.36%) As of 12:57 PM EasternTaysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? NVIDIA Regains Top Spot; FOMO Is Why It Will Continue to Rise Robinhood Stock Keeps Giving Investors Reasons To Buy Hims & Hers Stock: Buy the Dip or Wait It Out? Boeing: Analyst Upgrades & Order Boom Signal Clearer Skies CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast A New All-Time High Is Coming Soon for Credo Technology Group Guidewire Rockets Higher: A Move Above $300 Is Probable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
